Medical Honey for Wound Treatment in Intensive Care. (MICARéa) Randomized, Controlled, Single-center Pilot Study.

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Angers

About this trial

Wound management is a real public health issue in France. To date, a wide range of devices exists to treat these wounds, depending on their nature and stage of evolution. Honey has been proposed for the care of wounds and is effective in reducing the surface of wounds and the pain perceived by patients. Inanition, its use is very simple compared to usual care, requiring different types of dressing accross time. In the intensive care unit, patients are prone to suffering or developing numerous types of wound, but the interest of honey has not been investigated yet.

We propose a prospective, monocentric, randomized, single-blind, controlled clinical trial to assess the efficacy of managing acute cutaneous wounds with honey (Activon®) compared with standard care, in intensive care patients. The primary endpoint is the percentage of wound surface area reduction measured at 15 days from inclusion.

Eligibility criteria

Qualifiers

Hospitalization in surgical intensive care unit A -USC PTO CHU ANGERS

Informed consent signed by patient or relative (or emergency inclusion procedure)

Patient with one or more wounds ≥ 4 cm2, evolving for less than 8 days, including: stage 2, 3, 4 pressure sores, lacerations, ulcers, dermabrasions and scar disunions.

Disqualifiers

Patients with honey intolerance/allergy to bee stings

Patients with wounds lasting more than 8 days

Patient with a bleeding wound,

Patient with a tunneled wound

Trial design

Treatments tested in this trial

  • medical honey Activon® 25g Tube
  • standard of care

Treatment groups

60 Participants
are divided into 2 treatment groups

Sponsors and collaborators